Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Cat . Non | Espèces | Description du produit | Structure | Pureté | Caractéristique |
---|---|---|---|---|---|
ILR-H82F4 | Human | Biotinylated Human IL-4 R alpha / CD124 Protein, Fc,Avitag™ (MALS verified) |
|
||
ILR-H5253 | Human | Human IL-4 R alpha / CD124 Protein, Fc Tag (MALS verified) |
|
||
ILR-H82E9 | Human | Biotinylated Human IL-4 R alpha / CD124 Protein, Avitag™,His Tag (MALS verified) |
|
||
ILR-M5252 | Mouse | Mouse IL-4 R alpha / CD124 Protein, Fc Tag (MALS verified) |
|
||
ILR-M52H1 | Mouse | Mouse IL-4 R alpha / CD124 Protein, His Tag |
|
||
ILR-C52H8 | Cynomolgus / Rhesus macaque | Cynomolgus IL-4 R alpha / CD124 Protein, His Tag (MALS verified) |
|
||
ILR-C5258 | Cynomolgus / Rhesus macaque | Cynomolgus / Rhesus macaque IL-4 R alpha / CD124 Protein, Fc Tag |
|
||
ILR-H5221 | Human | Human IL-4 R alpha / CD124 Protein, His Tag (MALS verified) |
|
Immobilized Human IL-4, premium grade (Cat. No. IL4-H4218) at 5 μg/mL (100 μL/well)can bind Human IL-4 R alpha, Fc Tag (Cat. No. ILR-H5253) with a linear range of 1-20 ng/mL (QC tested).
The purity of Biotinylated Human IL-4 R alpha, Fc,Avitag (Cat. No. ILR-H82F4) is more than 90% and the molecular weight of this protein is around 120-147 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Dupilumab | SAR-231893; REGN-668 | Approved | Sanofi | Dupixent, 达必妥 | United States | Dermatitis, Atopic | Regeneron Pharmaceuticals Inc | 2017-03-28 | Asthma, Aspirin-Induced; Sinusitis; Asthma; Duodenitis; Pemphigoid, Bullous; Neurodermatitis; Colitis, Ulcerative; Urticaria; Prurigo; Pulmonary Disease, Chronic Obstructive; Paranasal Sinus Diseases; Sleep Apnea Syndromes; Peanut Hypersensitivity; Keloid; Scleroderma, Localized; Keratoconjunctivitis; Hypersensitivity, Immediate; Dermatitis, Atopic; Angioedema; Eczema; Hypersensitivity; Milk Hypersensitivity; Aspergillosis, Allergic Bronchopulmonary; Pruritus; Gastrointestinal Diseases; Respiratory Sounds; Alopecia Areata; Meningitis; Nasal Polyps; Chronic Urticaria; Respiratory Tract Diseases; Respiration Disorders; Eosinophilic gastroenteritis (EG); Coronavirus Disease 2019 (COVID-19); Dermatitis; Skin Diseases; Skin Diseases, Eczematous; Genetic Diseases, Inborn; Eosinophilic Esophagitis; Prostatic Neoplasms; Conjunctivitis, Allergic; Rhinitis, Allergic | Details |
Dupilumab | SAR-231893; REGN-668 | Approved | Sanofi | Dupixent, 达必妥 | United States | Dermatitis, Atopic | Regeneron Pharmaceuticals Inc | 2017-03-28 | Asthma, Aspirin-Induced; Sinusitis; Asthma; Duodenitis; Pemphigoid, Bullous; Neurodermatitis; Colitis, Ulcerative; Urticaria; Prurigo; Pulmonary Disease, Chronic Obstructive; Paranasal Sinus Diseases; Sleep Apnea Syndromes; Peanut Hypersensitivity; Keloid; Scleroderma, Localized; Keratoconjunctivitis; Hypersensitivity, Immediate; Dermatitis, Atopic; Angioedema; Eczema; Hypersensitivity; Milk Hypersensitivity; Aspergillosis, Allergic Bronchopulmonary; Pruritus; Gastrointestinal Diseases; Respiratory Sounds; Alopecia Areata; Meningitis; Nasal Polyps; Chronic Urticaria; Respiratory Tract Diseases; Respiration Disorders; Eosinophilic gastroenteritis (EG); Coronavirus Disease 2019 (COVID-19); Dermatitis; Skin Diseases; Skin Diseases, Eczematous; Genetic Diseases, Inborn; Eosinophilic Esophagitis; Prostatic Neoplasms; Conjunctivitis, Allergic; Rhinitis, Allergic | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
siLR4A | siLR4A | Phase 3 Clinical | National Skin Centre, Singapore | Keloid; Wounds and Injuries | Details |
GR-1802 | GR-1802; GR1802 | Phase 3 Clinical | Genrix (Shanghai) Biopharmaceutical Co Ltd | Rhinitis, Allergic, Seasonal; Nasal Polyps; Nose Diseases; Chronic Urticaria; Rhinitis, Allergic; Sinusitis; Asthma; Dermatitis, Atopic | Details |
Manfidokimab | AK-120 (Akeso ) | Phase 3 Clinical | Zhongshan Akeso Biopharma Co Ltd | Asthma; Dermatitis, Atopic | Details |
Comekibart | MG-010; MG-K-10; BC-005; MG-K10 | Phase 3 Clinical | Dragonboat Biopharmaceutical | Nasal Polyps; Asthma; Sinusitis; Dermatitis, Atopic | Details |
Recombinant anti-IL-4Rα humanized monoclonal antibody (Sansheng Guojian) | 611; 611 Q2W; 611 Q4W; 611-3SBio; SSGJ-611 | Phase 3 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Nasal Polyps; Polyps; Sinusitis; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic | Details |
Rademikibart | CBP-201 | Phase 2 Clinical | Suzhou Connect Biopharmaceuticals Ltd | Nasal Polyps; Nose Diseases; Iron deficiency; Sinusitis; Status Asthmaticus; Asthma; Dermatitis, Atopic | Details |
QX-005N | QX-005N | Phase 2 Clinical | Qyuns Therapeutics Co Ltd | Chronic Urticaria; Nasal Polyps; Prurigo; Asthma; Sinusitis; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic | Details |
BA-2101 | BA-2101; BA2101; PR-103; PR103 | Phase 2 Clinical | Pruritus; Chronic Urticaria; Nasal Polyps; Sinusitis; Asthma; Prurigo; Urticaria; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic | Details | |
Sorafenib Tosylate/Comekibart | MG-D-1609 | Phase 2 Clinical | Metagone Biotech Inc | Solid tumours | Details |
TQH2722 | TQH-2722; TQH2722 | Phase 2 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Nasal Polyps; Sinusitis; Dermatitis, Atopic | Details |
LQ-036 | LQ-036 | Phase 2 Clinical | Shanghai Novamab Biopharmaceuticals Co Ltd | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
SHR-1819 | SHR-1819 | Phase 2 Clinical | Atridia Pty Ltd | Nasal Polyps; Sinusitis; Asthma; Dermatitis, Atopic | Details |
Bizaxofusp | PRX-321; MDNA-55; IL4-PE; NBI-3001 | Phase 2 Clinical | Neurocrine Biosciences Inc, National Institute of Health, Islamabad | Kidney Neoplasms; HIV Infections; Glioblastoma; Small Cell Lung Carcinoma; Central Nervous System Neoplasms; Brain Neoplasms; Breast Neoplasms; Lung Neoplasms; Glioma; Sarcoma, Kaposi | Details |
Elarekibep | PRS-060/AZD1402; PRS-060; AZD-1402 | Phase 1 Clinical | University Of Melbourne, Pieris Pharmaceuticals | Asthma | Details |
NM26-2198 | NM-26-2198 | Phase 1 Clinical | Kaken Pharmaceutical Co Ltd, Numab Therapeutics Ag | Inflammation; Dermatitis, Atopic | Details |
IBI-3002 | IBI3002; IBI-3002 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Asthma | Details |
APG-808 | APG808; PR-001; PR001; APG-808 | Phase 1 Clinical | Paragon Therapeutics Inc, Apogee Therapeutics Inc | Pulmonary Disease, Chronic Obstructive | Details |
RC-1416 | Phase 1 Clinical | Nanjing Rongjiekang Biotechnology Co Ltd | Asthma | Details | |
HY-1770 | HY1770; HT-17; HT17; HY-1770 | Phase 1 Clinical | Suzhou Pharmavan Co Ltd | Dermatitis, Atopic; Plaque psoriasis | Details |
siLR4A | siLR4A | Phase 3 Clinical | National Skin Centre, Singapore | Keloid; Wounds and Injuries | Details |
GR-1802 | GR-1802; GR1802 | Phase 3 Clinical | Genrix (Shanghai) Biopharmaceutical Co Ltd | Rhinitis, Allergic, Seasonal; Nasal Polyps; Nose Diseases; Chronic Urticaria; Rhinitis, Allergic; Sinusitis; Asthma; Dermatitis, Atopic | Details |
Manfidokimab | AK-120 (Akeso ) | Phase 3 Clinical | Zhongshan Akeso Biopharma Co Ltd | Asthma; Dermatitis, Atopic | Details |
Comekibart | MG-010; MG-K-10; BC-005; MG-K10 | Phase 3 Clinical | Dragonboat Biopharmaceutical | Nasal Polyps; Asthma; Sinusitis; Dermatitis, Atopic | Details |
Recombinant anti-IL-4Rα humanized monoclonal antibody (Sansheng Guojian) | 611; 611 Q2W; 611 Q4W; 611-3SBio; SSGJ-611 | Phase 3 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Nasal Polyps; Polyps; Sinusitis; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic | Details |
Rademikibart | CBP-201 | Phase 2 Clinical | Suzhou Connect Biopharmaceuticals Ltd | Nasal Polyps; Nose Diseases; Iron deficiency; Sinusitis; Status Asthmaticus; Asthma; Dermatitis, Atopic | Details |
QX-005N | QX-005N | Phase 2 Clinical | Qyuns Therapeutics Co Ltd | Chronic Urticaria; Nasal Polyps; Prurigo; Asthma; Sinusitis; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic | Details |
BA-2101 | BA-2101; BA2101; PR-103; PR103 | Phase 2 Clinical | Pruritus; Chronic Urticaria; Nasal Polyps; Sinusitis; Asthma; Prurigo; Urticaria; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic | Details | |
Sorafenib Tosylate/Comekibart | MG-D-1609 | Phase 2 Clinical | Metagone Biotech Inc | Solid tumours | Details |
TQH2722 | TQH-2722; TQH2722 | Phase 2 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Nasal Polyps; Sinusitis; Dermatitis, Atopic | Details |
LQ-036 | LQ-036 | Phase 2 Clinical | Shanghai Novamab Biopharmaceuticals Co Ltd | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
SHR-1819 | SHR-1819 | Phase 2 Clinical | Atridia Pty Ltd | Nasal Polyps; Sinusitis; Asthma; Dermatitis, Atopic | Details |
Bizaxofusp | PRX-321; MDNA-55; IL4-PE; NBI-3001 | Phase 2 Clinical | Neurocrine Biosciences Inc, National Institute of Health, Islamabad | Kidney Neoplasms; HIV Infections; Glioblastoma; Small Cell Lung Carcinoma; Central Nervous System Neoplasms; Brain Neoplasms; Breast Neoplasms; Lung Neoplasms; Glioma; Sarcoma, Kaposi | Details |
Elarekibep | PRS-060/AZD1402; PRS-060; AZD-1402 | Phase 1 Clinical | University Of Melbourne, Pieris Pharmaceuticals | Asthma | Details |
NM26-2198 | NM-26-2198 | Phase 1 Clinical | Kaken Pharmaceutical Co Ltd, Numab Therapeutics Ag | Inflammation; Dermatitis, Atopic | Details |
IBI-3002 | IBI3002; IBI-3002 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Asthma | Details |
APG-808 | APG808; PR-001; PR001; APG-808 | Phase 1 Clinical | Paragon Therapeutics Inc, Apogee Therapeutics Inc | Pulmonary Disease, Chronic Obstructive | Details |
RC-1416 | Phase 1 Clinical | Nanjing Rongjiekang Biotechnology Co Ltd | Asthma | Details | |
HY-1770 | HY1770; HT-17; HT17; HY-1770 | Phase 1 Clinical | Suzhou Pharmavan Co Ltd | Dermatitis, Atopic; Plaque psoriasis | Details |
This web search service is supported by Google Inc.